Armata Pharmaceuticals, Inc.
Price Action
Technical Summary
EMERGING TRENDArmata Pharmaceuticals, Inc. shows underlying uptrend characteristics but has temporarily lost support at the 50-day moving average. Relative strength is leading (RS Rating: 91), indicating clear outperformance against the broad market. Earnings contraction of 393% provides fundamental context to the price action. Investors should exercise caution due to high volatility (124% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $11.25 | -18.68% | BELOW |
| 50 SMA | $10.63 | -13.95% | BELOW |
| 100 SMA | $8.85 | +3.42% | ABOVE |
| 150 SMA | $7.69 | +19.04% | ABOVE |
| 200 SMA | $6.44 | +42.09% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is ARMP in an uptrend right now?
ARMP has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is ARMP overbought or oversold?
ARMP's RSI (14) is 42. The stock is in neutral territory, neither overbought nor oversold.
Is ARMP outperforming the market?
ARMP has a Relative Strength (RS) Rating of 91 out of 99. Yes, ARMP is a market leader, outperforming 91% of all stocks over the past 12 months.
Where is ARMP in its 52-week range?
ARMP is trading at $9.15, which is 56% of its 52-week high ($16.34) and 53% above its 52-week low ($1.17).
How volatile is ARMP?
ARMP has a Beta of 1.44 and 52-week volatility of 124%. It's more volatile than the S&P 500 - expect bigger swings.